

Editorial

2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

Semin Thromb Hemost 2015;41:673–679.



Eberhard F. Mammen
(1930–2008).

Welcome to the latest of our Eberhard F. Mammen award announcements. As noted previously,^{1–3} Thieme, the publisher of *Seminars in Thrombosis & Hemostasis*, has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard F. Mammen and in recognition of his contribution to this field and to the journal that he both founded and steered for more than three decades. These awards began in 2009, under two categories: “Most Popular Article Awards” and “Young Investigator Awards.” Current details and conditions of the award can be summarized as:

- **Most Popular article awards:** Awarded to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis*. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters to the Editor, Editorials, and previous award winners are excluded from further consideration of these awards, which currently comprise two categories: one for “open access” articles and another for a “general category.” There are two major cash prizes of US\$1,000 for each category. In addition, winners of the “general category” awards are granted “open access” status for these articles thereafter.
- **Young Investigator awards:** Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of US\$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other article related to the topic of their presentation for publication in *Seminars in Thrombosis & Hemostasis*.

Further details of the awards and the award winners are posted online (<http://www.thieme.com/sth>), and previous award winner announcements are also available in print.^{4–11}

It is, therefore, with great pleasure that we would like to announce the latest winners of the 2015 Eberhard F. Mammen awards for the most popular articles from *Seminars in Thrombosis & Hemostasis* for the period of 2013 to 2014 inclusive. We will be announcing the young investigator awards related to meetings held in the recent past at a forthcoming opportunity.

2015 “Most Popular” Article Awards

As mentioned, the Most Popular article awards are given to the authors of the most popular articles published in *Seminars in Thrombosis & Hemostasis* as determined on the basis of user statistics from the publisher of this journal and covering the preceding 2-year period. Thus, the 2015 “Most Popular” awards are granted to the most popular articles from 2013 to 2014 inclusive. Because of an increasing trend to publish in an open access mode, and due to ongoing presence of many of the previous “Most Popular” awardees (now also open access) on the top 100 listing of most popular, this may generate an inequitable advantage for these in terms of download statistics. Accordingly, the publisher of *Seminars in Thrombosis & Hemostasis* has established a separate category of the award for “open access” articles, and the most popular articles are now listed in two separate tables. ➤ **Table 1** lists the top 25 downloaded non-open access articles from *Seminars in Thrombosis & Hemostasis* (2013 and 2014 inclusive), and thus eligible for the “general category” award.^{12–36} ➤ **Table 2** lists the top 25 downloaded open access articles from *Seminars in*

Address for correspondence
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme Tissue Factor in Arterial and Venous Thrombosis: From Pathophysiology to Clinical Implications; Guest Editors: Vincenzo Toschi, MD, and Massimo Franchini, MD.

Copyright © 2015 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0035-1564814>.
ISSN 0094-6176.

Table 1 Most popular papers from *Seminars in Thrombosis & Hemostasis* in 2013/2014 “general category”

Rank, citation
1. Tapson VF. Thrombolytic therapy for acute pulmonary embolism. <i>Semin Thromb Hemost</i> 2013;39(4):452–458
2. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. <i>Semin Thromb Hemost</i> 2013;39(2):153–160
3. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. <i>Semin Thromb Hemost</i> 2013;39(5):559–566
4. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. <i>Semin Thromb Hemost</i> 2013;39(6):585–595
5. Scharf RE. Drugs that affect platelet function. <i>Semin Thromb Hemost</i> 2012;38(8):865–883
6. Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. <i>Semin Thromb Hemost</i> 2013;39(2):191–201
7. Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. <i>Semin Thromb Hemost</i> 2013;39(7):772–778
8. Barbano B, Gigante A, Amoroso A, Cianci R. Thrombosis in nephrotic syndrome. <i>Semin Thromb Hemost</i> 2013;39(5):469–476
9. Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. <i>Semin Thromb Hemost</i> 2010;36(8):807–818
10. McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. <i>Semin Thromb Hemost</i> 2013;39(1):101–111
11. Barco S, Nijkeuter M, Middeldorp S. Pregnancy and venous thromboembolism. <i>Semin Thromb Hemost</i> 2013;39(5):549–558
12. Franchini M, Coppola A, Rocino A, et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. <i>Semin Thromb Hemost</i> 2013;39(7):752–766
13. Tagalakis V, Wharin C, Kahn SR. Comprehensive update on the prevention and treatment of venous thromboembolism in cancer patients. <i>Semin Thromb Hemost</i> 2013;39(2):127–140
14. Monagle P. Diagnosis and management of deep venous thrombosis and pulmonary embolism in neonates and children. <i>Semin Thromb Hemost</i> 2012;38(7):683–690
15. Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. <i>Semin Thromb Hemost</i> 2003;29(5):435–450
16. Schroeder V, Kohler HP. Factor XIII deficiency: an update. <i>Semin Thromb Hemost</i> 2013;39(6):632–641
17. Lippi G, Mattiuzzi C, Favaloro EJ. Novel and emerging therapies: thrombus-targeted fibrinolysis. <i>Semin Thromb Hemost</i> 2013;39(1):48–58
18. Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. <i>Semin Thromb Hemost</i> 2013;39(4):356–364
19. Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. <i>Semin Thromb Hemost</i> 2012;38(5):454–462
20. Duga S, Salomon O. Congenital factor XI deficiency: an update. <i>Semin Thromb Hemost</i> 2013;39(6):621–631
21. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. <i>Semin Thromb Hemost</i> 2002;28(3):247–256
22. Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. <i>Semin Thromb Hemost</i> 2013;39(7):840–846
23. Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. <i>Semin Thromb Hemost</i> 2011;37(3):237–251
24. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. <i>Semin Thromb Hemost</i> 2004;30(5):579–589
25. Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. <i>Semin Thromb Hemost</i> 2012;38(5):483–496

Thrombosis & Hemostasis (2013 and 2014 inclusive), including previous winners of this award.^{37–61} As previously highlighted in these editorials,^{9,10} previous winners of the award are not eligible for another award for the same article; hence, many of the articles listed in **Table 2** do not qualify for an award in 2015. The notable exceptions are the other top-listed articles, the first two of which have, therefore,

been granted the award,^{41,43} with both being published in 2013. The two top-listed articles^{12,13} in **Table 1** are winners of the 2015 Eberhard F. Mammen award for most popular article within the “general category”, both also being published in 2013. Accordingly, the 2015 Eberhard F. Mammen award winners for most popular article (2014/2014 inclusive) are as follows:

Table 2 Most popular papers from *Seminars in Thrombosis & Hemostasis* in 2013/2014 “open access” category

Rank, citation	Award won in previous years?
1. Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. <i>Semin Thromb Hemost</i> 2010;36(1):59–70	2012
2. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. <i>Semin Thromb Hemost</i> 2005;31(4):381–392	2009
3. Rak J. Microparticles in cancer. <i>Semin Thromb Hemost</i> 2010;36(8):888–906	2012
4. Mariani G, Bernardi F. Factor VII Deficiency. <i>Semin Thromb Hemost</i> 2009;35(4):400–406	2011
5. Hylek EM. Anticoagulation therapy for atrial fibrillation. <i>Semin Thromb Hemost</i> 2013;39(2):147–152	–
6. Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. <i>Semin Thromb Hemost</i> 2011;37(3):267–274	2013
7. Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. <i>Semin Thromb Hemost</i> 2013;39(2):117–126	–
8. Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. <i>Semin Thromb Hemost</i> 2012;38(7):673–682	–
9. Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. <i>Semin Thromb Hemost</i> 2011;37(3):280–297	2013
10. Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. <i>Semin Thromb Hemost</i> 2014;40(1):60–65	–
11. Italiano JE Jr. Unraveling mechanisms that control platelet production. <i>Semin Thromb Hemost</i> 2013;39(1):15–24	–
12. Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23–30	2014
13. Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. <i>Semin Thromb Hemost</i> 2014;40(1):106–114	–
14. Favaloro EJ. Clinical utility of the PFA-100. <i>Semin Thromb Hemost</i> 2008;34(8):709–733	–
15. Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. <i>Semin Thromb Hemost</i> 2012;38(1):47–54	2014
16. Althaus K, Greinacher A. MYH9-related platelet disorders. <i>Semin Thromb Hemost</i> 2009;35(2):189–203	–
17. Bunimov N, Fuller N, Hayward CP. Genetic loci associated with platelet traits and platelet disorders. <i>Semin Thromb Hemost</i> 2013;39(3):291–305	–
18. Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. <i>Semin Thromb Hemost</i> 2011;37(7):802–809	2014
19. Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. <i>Semin Thromb Hemost</i> 2014;40(1):121–128	–
20. Raskob GE, Angchaisuksiri P, Blanco AN, et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. <i>Semin Thromb Hemost</i> 2014;40(7):724–735	–
21. Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. <i>Semin Thromb Hemost</i> 2014;40(3):277–283	–
22. Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. <i>Semin Thromb Hemost</i> 2008;34(8):772–778	–
23. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. <i>Semin Thromb Hemost</i> 2008;34(1):58–73	2010
24. Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. <i>Semin Thromb Hemost</i> 2014;40(2):163–171	–
25. Harenberg J, Kraemer S, Du S, et al. Determination of direct oral anticoagulants from human serum samples. <i>Semin Thromb Hemost</i> 2014;40(1):129–134	–

General Category

1. Tapson VF. Thrombolytic therapy for acute pulmonary embolism. *Semin Thromb Hemost* 2013;39(4):452–458
2. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. *Semin Thromb Hemost* 2013;39(2):153–160

Open Access Category

1. Hylek EM. Anticoagulation therapy for atrial fibrillation. *Semin Thromb Hemost* 2013;39(2):147–152
2. Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. *Semin Thromb Hemost* 2013;39(2):117–126

All the authors of these award winning articles were thrilled to hear that their articles had won an Eberhard F. Mammen most popular award, and provided the following additional responses:

From Dr. Victor Tapson (► **Fig. 1**), Professor of Medicine at Cedars-Sinai Medical Center (Los Angeles, CA):

I was delighted to hear that my article ‘Thrombolytic therapy for acute pulmonary embolism’ had won an Eberhard Mammen *Seminars in Thrombosis & Hemostasis* 2015 most popular article award. The issues surrounding thrombolytic therapy continue to be vexing to clinicians. Even 40 years after publication of Urokinase/Streptokinase Pulmonary Embolism (PE) Trials, the indications for systemic thrombolysis, particularly in submassive PE, remain cloudy. Although the largest study to date has indicated no clear mortality difference when thrombolytics are administered in submassive PE, a large meta-analysis subsequently suggested improved mortality in this group. Clearly, these patients still require careful analysis of their clinical data including assessment for bleeding risk. Recently, catheter-based therapy (with or without thrombolysis) has entered the clinical arena, offering more clinical options but requiring analysis of resources, interpretation of the available clinical data, and assessment of



Fig. 1 Dr. Victor Tapson.



Fig. 2 Dr. James N. George.

the individual patient. We do not yet have clear guidelines, but we are moving in a good direction. We are embarking on new trials in this field. Because of the acute nature of these patients, the dilemma of whether to proceed with thrombolysis remains of tremendous interest to clinicians. Dr. Eberhard Mammen went to medical school in Germany, intending to take over his father’s family practice. Those of us in the field of venous thromboembolism are very fortunate that he ultimately became involved in research, in addition to medical education and clinical practice.

From Dr. James N. George (► **Fig. 2**), George Lynn Cross Professor, Medicine University of Oklahoma Health Sciences Center (Oklahoma City, OK):

This project was part of Dr. Roseleen Charania’s [► **Fig. 3**] Hematology-Oncology fellowship effort. We have had a lot of experience with patients who were initially suspected to have thrombotic thrombocytopenic purpura (TTP) but subsequently were discovered to have another etiology for



Fig. 3 Dr. Roseleen Charania.



Fig. 4 Dr. Elaine M. Hylek.



Fig. 5 Dr. David Garcia.

the microangiopathic hemolytic anemia and thrombocytopenia. There have been many different etiologies. Dr. Charania's goal was to describe how we evaluate these patients. She did a superb job organizing our experience and presenting the critical points for patient evaluations. This was a great clinical project for her. She and I both learned a lot.

From Dr. Elaine M. Hylek (–**Fig. 4**), Director Thrombosis Clinic and Anticoagulation Service at Boston University Medical Center (Boston, MA):

When I learned that I had received this award, I could not believe it. It is a true honor, especially coming from this community. The world of thrombosis has grown increasingly complex from basic mechanisms and treatments to the varied clinical settings and high-risk patients. Understanding the risks and benefits and helping our patients and colleagues make the most informed decisions was the overarching aim of this article.

Dr. David Garcia (–**Fig. 5**), Professor of Medicine, University of Washington (Seattle, Washington), provided the following commentary:



Fig. 6 Dr. Cristhiam Rojas-Hernandez.

I am honored to receive one of the Eberhard Mammen *Seminars in Thrombosis & Hemostasis* 2015 Most Popular Article Awards. In my position, I am often asked to write review papers and I do occasionally wonder how many people benefit from the effort it takes to complete such a manuscript. In this case, I had the help of a superb colleague, Dr. Cristhiam Rojas-Hernandez (now a member of the Section of Benign Hematology at MD Anderson Cancer Center) [–**Fig. 6**]. We were fortunate to be invited to write this paper at a moment when there was a great deal of recently published, clinically actionable information available about the direct oral anticoagulants (DOACs), and I am very pleased to know that many *Seminars* readers found our synthesis of the evidence to be useful.

It is also interesting (as always) to reflect on some of the other most popular articles which relate to a variety of topics within the field of thrombosis and hemostasis. Of some continued interest, and analogous to previous years, is that many articles from previous most popular award listings appear yet again (–**Table 2**), and this highlights their perpetuating interest to our readership.

I would like as always to thank not only all of the authors listed in –**Tables 1** and **2** but also the contributing authors that did not manage to make these listings, as well as all the guest editors of issues recently published in *Seminars in Thrombosis & Hemostasis*. I look forward to seeing future listings!

References

- 1 Favaloro EJ. Editorial. Welcome to a special issue of *Seminars in Thrombosis & Hemostasis*—The Closing Issue for 2008. *Semin Thromb Hemost* 2008;34:693–696
- 2 Favaloro EJ. Preface. A tribute to Eberhard F. Mammen, M.D. (1930–2008). *Semin Thromb Hemost* 2008;34(8):703–707
- 3 Favaloro EJ. Editorial. Welcome to the first issue of *Seminars in Thrombosis & Hemostasis* for 2009. *Semin Thromb Hemost* 2009; 35:1–2

- 4 Favalaro EJ. Editorial. Winners of the inaugural Eberhard F. Mammen award for most popular article. *Semin Thromb Hemost* 2009; 35:587–590
- 5 Favalaro EJ. Editorial. 2009 Eberhard F. Mammen young investigator award winners. *Semin Thromb Hemost* 2010;36:469–470
- 6 Favalaro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. *Semin Thromb Hemost* 2010;36(7):685–692
- 7 Favalaro EJ. 2011 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2011;37(5):431–439
- 8 Favalaro EJ. 2012 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2012;38(5):425–432
- 9 Favalaro EJ. 2013 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2013;39(6):567–574
- 10 Favalaro EJ. 2014 Eberhard F. Mammen award announcements: part I - most popular articles. *Semin Thromb Hemost* 2014;40(4):407–412
- 11 Favalaro EJ. 2014 Eberhard F. Mammen award announcements: part II-Young Investigator Awards. *Semin Thromb Hemost* 2014; 40(7):718–723
- 12 Tapson VF. Thrombolytic therapy for acute pulmonary embolism. *Semin Thromb Hemost* 2013;39(4):452–458
- 13 George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. *Semin Thromb Hemost* 2013;39(2):153–160
- 14 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. *Semin Thromb Hemost* 2013;39(5):559–566
- 15 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. *Semin Thromb Hemost* 2013;39(6):585–595
- 16 Scharf RE. Drugs that affect platelet function. *Semin Thromb Hemost* 2012;38(8):865–883
- 17 Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. *Semin Thromb Hemost* 2013;39(2):191–201
- 18 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. *Semin Thromb Hemost* 2013;39(7):772–778
- 19 Barbano B, Gigante A, Amoroso A, Cianci R. Thrombosis in nephrotic syndrome. *Semin Thromb Hemost* 2013;39(5):469–476
- 20 Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. *Semin Thromb Hemost* 2010;36(8):807–818
- 21 McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. *Semin Thromb Hemost* 2013;39(1):101–111
- 22 Barco S, Nijkeuter M, Middeldorp S. Pregnancy and venous thromboembolism. *Semin Thromb Hemost* 2013;39(5):549–558
- 23 Franchini M, Coppola A, Rocino A, et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. *Semin Thromb Hemost* 2013;39(7):752–766
- 24 Tagalakakis V, Wharin C, Kahn SR. Comprehensive update on the prevention and treatment of venous thromboembolism in cancer patients. *Semin Thromb Hemost* 2013;39(2):127–140
- 25 Monagle P. Diagnosis and management of deep venous thrombosis and pulmonary embolism in neonates and children. *Semin Thromb Hemost* 2012;38(7):683–690
- 26 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. *Semin Thromb Hemost* 2003;29(5):435–450
- 27 Schroeder V, Kohler HP. Factor XIII deficiency: an update. *Semin Thromb Hemost* 2013;39(6):632–641
- 28 Lippi G, Mattiuzzi C, Favalaro EJ. Novel and emerging therapies: thrombus-targeted fibrinolysis. *Semin Thromb Hemost* 2013; 39(1):48–58
- 29 Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. *Semin Thromb Hemost* 2013;39(4):356–364
- 30 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. *Semin Thromb Hemost* 2012;38(5):454–462
- 31 Duga S, Salomon O. Congenital factor XI deficiency: an update. *Semin Thromb Hemost* 2013;39(6):621–631
- 32 Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. *Semin Thromb Hemost* 2002; 28(3):247–256
- 33 Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. *Semin Thromb Hemost* 2013;39(7):840–846
- 34 Lippi G, Favalaro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. *Semin Thromb Hemost* 2011;37(3):237–251
- 35 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. *Semin Thromb Hemost* 2004;30(5):579–589
- 36 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. *Semin Thromb Hemost* 2012;38(5):483–496
- 37 Lippi G, Franchini M, Favalaro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. *Semin Thromb Hemost* 2010;36(1):59–70
- 38 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. *Semin Thromb Hemost* 2005;31(4):381–392
- 39 Rak J. Microparticles in cancer. *Semin Thromb Hemost* 2010;36(8):888–906
- 40 Mariani G, Bernardi F. Factor VII deficiency. *Semin Thromb Hemost* 2009;35(4):400–406
- 41 Hylek EM. Anticoagulation therapy for atrial fibrillation. *Semin Thromb Hemost* 2013;39(2):147–152
- 42 Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. *Semin Thromb Hemost* 2011;37(3):267–274
- 43 Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. *Semin Thromb Hemost* 2013;39(2):117–126
- 44 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. *Semin Thromb Hemost* 2012;38(7):673–682
- 45 Fava C, Montagnana M, Favalaro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. *Semin Thromb Hemost* 2011;37(3):280–297
- 46 Lippi G, Favalaro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. *Semin Thromb Hemost* 2014;40(1):60–65
- 47 Italiano JE Jr. Unraveling mechanisms that control platelet production. *Semin Thromb Hemost* 2013;39(1):15–24
- 48 Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. *Semin Thromb Hemost* 2012;38(1):23–30
- 49 Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. *Semin Thromb Hemost* 2014;40(1):106–114
- 50 Favalaro EJ. Clinical utility of the PFA-100. *Semin Thromb Hemost* 2008;34(8):709–733
- 51 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. *Semin Thromb Hemost* 2012;38(1):47–54
- 52 Althaus K, Greinacher A. MYH9-related platelet disorders. *Semin Thromb Hemost* 2009;35(2):189–203

- 53 Bunimov N, Fuller N, Hayward CP. Genetic loci associated with platelet traits and platelet disorders. *Semin Thromb Hemost* 2013;39(3):291–305
- 54 Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. *Semin Thromb Hemost* 2011;37(7):802–809
- 55 Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. *Semin Thromb Hemost* 2014;40(1):121–128
- 56 Raskob GE, Angchaisuksiri P, Blanco AN, et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. *Semin Thromb Hemost* 2014;40(7):724–735
- 57 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. *Semin Thromb Hemost* 2014;40(3):277–283
- 58 Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. *Semin Thromb Hemost* 2008;34(8):772–778
- 59 Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. *Semin Thromb Hemost* 2008;34(1):58–73
- 60 Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. *Semin Thromb Hemost* 2014;40(2):163–171
- 61 Harenberg J, Kraemer S, Du S, et al. Determination of direct oral anticoagulants from human serum samples. *Semin Thromb Hemost* 2014;40(1):129–134